Real-World check: does aflibercept 8 mg hold up outside the lab?
NCT ID NCT06075147
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This observational study will follow 2,500 adults with vision loss from nAMD or DME who are already prescribed aflibercept 8 mg by their doctors. Researchers will collect data from routine visits over up to 24 months to see how vision changes. The goal is to understand how well the drug works in real-world settings, not in a controlled trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aflibercept 8 mg (eye injection)
- What this could lead to
- If successful, this study will provide real-world evidence on how well aflibercept 8 mg works for vision loss due to nAMD and DME, supporting its use in routine care.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new treatment but gathers data on an already approved drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULA EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many Locations
Multiple Locations, Australia
-
Many Locations
Multiple Locations, Canada
-
Many Locations
Multiple Locations, Denmark
-
Many Locations
Multiple Locations, Finland
-
Many Locations
Multiple Locations, France
-
Many Locations
Multiple Locations, Germany
-
Many Locations
Multiple Locations, Italy
-
Many Locations
Multiple Locations, Japan
-
Many Locations
Multiple Locations, Netherlands
-
Many Locations
Multiple Locations, Norway
-
Many Locations
Multiple Locations, Portugal
-
Many Locations
Multiple Locations, Saudi Arabia
-
Many Locations
Multiple Locations, South Korea
-
Many Locations
Multiple Locations, Spain
-
Many Locations
Multiple Locations, Sweden
-
Many Locations
Multiple Locations, Switzerland
-
Many Locations
Multiple Locations, United Arab Emirates
-
Many Locations
Multiple Locations, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene therapy tame wet AMD for years?
- Laser zap before eye injection could cut needle count for wet AMD
- App aims to shield visually impaired youth from social media's body image pitfalls
- Could a smartphone app help babies see better?
- New app could let blind people pick the safest route before they walk
- Adapted exercise program aims to boost health and social skills in visually impaired youth